SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

🎯 Drug Targets

Browse 13 drug targets with druggability analysis, composite scores, and clinical context

13
Targets
2
High Druggability
0.62
Avg Score
15
Target Classes
Druggability Distribution
High: 2Medium: 7Low: 4Unknown: 0
Avg druggability score: 0.576
Clinical Pipeline
Approved: 10Phase III: 0Phase II: 2Phase I: 1Preclinical: 0
Total compounds: 52 · Approved: 30
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Receptor (11) Transcription Factor (11) Ligand (10) Epigenetic Regulator (8) Transporter (8) Kinase (7) Other (4) Protease (4) Chaperone (4)
Druggability Low (97) Medium (56) Undruggable (19) High (10) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=GPCR — 13 results
DRD2 Dopamine receptor D2 Approved
Gpcr High Druggability
Score
0.69
Drug.
0.90
Safety
0.60
Drugs
14
Hyps
1
Papers
18
Small molecule agonist or antagonist modulating dopamine signaling
MTNR1A Melatonin receptor 1A Approved
Gpcr Medium Druggability
Score
0.67
Drug.
0.57
Safety
0.80
Drugs
3
Hyps
2
Papers
48
Small molecule agonists that activate G-protein coupled receptor signaling
P2RY1 P2Y purinoreceptor 1 Phase I
Gpcr Low Druggability
Score
0.65
Drug.
0.41
Safety
0.60
Drugs
1
Hyps
7
Papers
29
GPCR antagonists or agonists modulating purinergic signaling
MTNR1B Melatonin receptor 1B Approved
Gpcr High Druggability
Score
0.64
Drug.
0.90
Safety
0.80
Drugs
3
Hyps
2
Papers
17
Small molecule agonists that activate G-protein coupled receptor signaling
GLP1R Glucagon-like peptide-1 receptor Approved
Gpcr Medium Druggability
Score
0.64
Drug.
0.64
Safety
0.80
Drugs
3
Hyps
1
Papers
0
GLP-1 receptor agonist peptides and small molecule modulators
ADORA2A Adenosine A2A receptor Approved
Gpcr Medium Druggability
Score
0.62
Drug.
0.57
Safety
0.70
Drugs
12
Hyps
1
Papers
31
Small molecule antagonists blocking adenosine A2A receptor signaling
ADRA2A Alpha-2A adrenergic receptor Approved
Gpcr Medium Druggability
Score
0.61
Drug.
0.59
Safety
0.60
Drugs
2
Hyps
1
Papers
31
Small molecule agonists and antagonists modulating noradrenergic signaling
HCRTR1 Hypocretin Receptor 1 Approved
Gpcr Medium Druggability
Score
0.60
Drug.
0.60
Safety
0.70
Drugs
2
Hyps
3
Papers
26
Small molecule antagonist blocking orexin receptor signaling
HCRTR2 Hypocretin Receptor 2 Approved
Gpcr Medium Druggability
Score
0.59
Drug.
0.60
Safety
0.70
Drugs
2
Hyps
3
Papers
57
Small molecule antagonist blocking orexin receptor signaling
P2RY12 P2Y purinoreceptor 12 Approved
Gpcr Medium Druggability
Score
0.59
Drug.
0.55
Safety
0.50
Drugs
3
Hyps
6
Papers
44
P2Y12 receptor antagonists blocking ADP-mediated signaling
CX3CR1 C-X3-C Motif Chemokine Receptor 1 Phase II
Gpcr Low Druggability
Score
0.59
Drug.
0.44
Safety
0.50
Drugs
2
Hyps
12
Papers
25
GPCR antagonist modulating microglial activation and neuroinflammation
GPR37 G-protein coupled receptor 37 Approved
Gpcr Low Druggability
Score
0.57
Drug.
0.30
Safety
0.60
Drugs
2
Hyps
2
Papers
31
GPR37 agonists or modulators would activate the receptor to promote dopaminergic neuron survival and neuroprotection, counteracting the neurodegeneration characteristic of Parkinson's disease. Ligands binding to GPR37 would enhance G-protein signaling cascades that support neuronal viability and function.
CMKLR1 Chemokine-like Receptor 1 Phase II
Gpcr Low Druggability
Score
0.55
Drug.
0.41
Safety
0.60
Drugs
3
Hyps
1
Papers
31
GPCR antagonist or agonist modulating chemerin signaling
Exchange | Dashboard